# Numab Therapeutics AG: Research, Horgen, Switzerland

> Numab Therapeutics AG: Numab Therapeutics AG is a clinical-stage biotechnology company based in Horgen, Switzerland, founded in 2011.

Source: https://millionrounds.com/startup/numab-therapeutics-ag (Millionrounds; every figure on the page links to its filing or article)

Switzerland · [Research startup](https://millionrounds.com/companies)

# Numab Therapeutics AG

Numab Therapeutics AG is a clinical-stage biotechnology company based in Horgen, Switzerland, founded in 2011.

Funding reported Last round: Series C

Research Horgen, Switzerland

Company summary

- **Founded:** 2011 15 years old
- **Team:** 73 51 to 200 people
- **Funding reported:** 202.8M as listed, currency not stated
- **Last round:** Series C Jan 2025

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Numab Therapeutics AG has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Numab Therapeutics AG

Numab Therapeutics AG is a clinical-stage biotechnology company based in Horgen, Switzerland, founded in 2011.

The company focuses on developing multi-specific antibody-based immunotherapies for inflammation and cancer, utilizing its proprietary platforms, λ-CapTM and MATCHTM. Numab aims to create first-in-class and best-in-class medicines that enhance patient outcomes through a reproducible therapeutic design process. The company specializes in oncology and inflammatory diseases, targeting non-traditional antibody targets, including complex membrane proteins. Numab's pipeline includes innovative assets like NM26, a bispecific antibody for atopic dermatitis, and NM32, a T-cell engager for solid tumors and hematological malignancies. In addition to its internal drug development, Numab offers discovery and development services to industry partners, including technology licensing and custom therapeutics. With over $223 million raised in funding, Numab is well-positioned to advance its mission in the biopharmaceutical landscape.

## What company datasets say Numab Therapeutics AG raised

Funding, as reported

Reported in all **202.8M** in the source's currency

Last round **Series C**

Last round size **55M**

Last round date **Jan 2025**

Investors listed **5**

## Founders and team

From Numab Therapeutics AG's own website: 12 on the team.

- **Barbara Angehrn** Chief Executive Officer
- **Alain Bertallo** Vice President, People & Culture
- **Andrew Fox** Senior Vice President, Development Operations
- **James Singleton** Chief Legal Officer
- **Raj Chopra** Chief Scientific Officer
- **Stefan Warmuth** Chief Technology Officer
- **Uyum Evcin** Head of Business Development
- **Carlo Incerti** Chairman of the Board
- **David Urech** Director, R&D Committee Chair
- **Matthias Fehr** Director, Audit & Risk Committee Chair
- **Michael K. Bauer** Director, Compensation Committee Chair
- **Oliver Middendorp** Director

## On a portfolio page

Investors who name them

- [Eisai Innovation](https://millionrounds.com/fund/eisai-innovation)

Each firm lists Numab Therapeutics AG on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

biotechnology research b2b

Built with from their website

Microsoft Exchange Microsoft 365 Apps & Services Microsoft Exchange Online Microsoft 365 Outlook Microsoft Email Providers

- **Sector:** Research
- **Industry code:** NAICS 541714, 325414, SIC 2834
- **Region:** Zurich
- **Revenue:** 17.1M a year, as listed

## Research in Switzerland

Startups like it

- [**Nouscom** Basel · founded 2015 *Raised*](https://millionrounds.com/company/nouscom)
- [**Hedera Dx** Epalinges · founded 2021 *Raised*](https://millionrounds.com/company/hedera-dx)
- [**Bio Protocol** Zug *Raised*](https://millionrounds.com/company/bio-protocol)
- [**InVirtuoLabs** Lugano · founded 2024 *Raised*](https://millionrounds.com/company/invirtuolabs)
- [**NEMIS Technologies** Waedenswil · founded 2018 *Raised*](https://millionrounds.com/company/nemis-technologies)
- [**Windward Bio** Basel](https://millionrounds.com/startup/windward-bio)
- [**Bright Peak Therapeutics** Basel · founded 2017](https://millionrounds.com/startup/bright-peak-therapeutics)
- [**Centenara Labs AG** Schlieren · founded 2019](https://millionrounds.com/startup/centenara-labs-ag)

## Is this your company?

Add your raise, your deck and your story, and put Numab Therapeutics AG in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)